Aortoiliac Occlusive Disease in Patients with Known or Suspected Peripheral Vascular Disease: Safety and Efficacy of Gadofosveset-enhanced MR Angiography—Multicenter Comparative Phase III Study

Rapp, Joseph H.; Wolff, Steven; Quinn, Stephen F.; Soto, Jorge A.; Meranze, Steven G.; Muluk, Satish C.; Blebea, John; Johnson, Stephen; Rofsky, Neil M.; Duerinckx, André J.; Foster, Gregory S.; Kent, K. Craig; Moneta, Gregory L.; Middlebrook, Michael R.; Narra, Vamsidhar R.; Toombs, Barry D.; Pollak, Jeffrey; Yucel, E K; Shamsi, Kohkan; Weisskoff, Robert M.

doi:10.1148/radiol.2361040148

Cited by 86 publications

(51 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings demonstrate that CE-MRA overcame some intrinsic limitations associated with noncontrast MRA in complex, tortuous, or turbulent flow vessels, such as diseased aortoiliac arteries and are consistent with those reported from another multicenter study (13). In this study we sought to answer two main questions: 1) Does CE-MRA improve the ability to diagnose aortoiliac stenoses compared with noncontrast enhanced MRA?…”

Section: Discussionsupporting

confidence: 75%

Comparison of contrast‐enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of peripheral arterial occlusive disease: Results of a phase III multicenter trial

Bui¹,

Miller²,

Mildenberger

et al. 2010

Magnetic Resonance Imaging

View full text Add to dashboard Cite

MPH 5 for the Omniscan MRA Investigator Panel Purpose: To evaluate the efficacy and safety of 0.1 mmol/ kg gadodiamide administration for contrast-enhanced magnetic resonance angiography (CE-MRA) in detecting hemodynamically relevant main stenosis (ie, !50% or occlusion) of aortoiliac arteries. Materials and Methods:In a multicenter, phase 3, controlled study, patients with suspected or proven peripheral arterial occlusive disease (PAOD) underwent CE-MRA with administration of gadodiamide. Intraarterial digital subtraction angiography (IA-DSA) was used as the reference. The study was approved by all Institutional Review Boards or Institutional Ethic Committees prior to commencement of patient recruitment and written informed consent was obtained from all patients.Results: Independent readers rated 25%-45% of CE-MRA images as excellent compared with 0.3%-6% of noncontrast MRA images. Mean imaging acquisition time for CE-MRA was <1 minute (0.7 6 1.9 minutes) versus 10 minutes (10.8 6 3.0) for noncontrast MRA. Sensitivity, specificity, and accuracy of CE-MRA were superior compared with those of noncontrast MRA in detecting significant arterial stenoses. Compared with IA-DSA, the sensitivity of CE-MRA ranged from 80%-88% and the specificity from 73% to 92% for the three blinded readers, at the patient level. Conclusion:Diagnostic results with CE-MRA were superior and more consistent compared with noncontrast MRA for detecting hemodynamically relevant main stenoses in patients with suspected or proven PAOD and compared favorably with IA-DSA as a reference standard.

show abstract

Section: Discussionsupporting

confidence: 75%

Comparison of contrast‐enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of peripheral arterial occlusive disease: Results of a phase III multicenter trial

Bui¹,

Miller²,

Mildenberger

et al. 2010

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…9 In our experience, inner-thigh and midsection burning and discomfort, sometimes described on more rapid injection of BPA, are mitigated by the slower injection rate prescribed in our studies. 21 Frydrychowicz et al 13 estimated both SNR and contrast-tonoise ratio (CNR) between SCA and BPA; however as they point out, and as thoroughly expounded previously by Reeder et al, 22 SNR and CNR measurements of multichannel receive datasets are not straightforward, given the spatial nonuniformity of noise amplification inherent to parallel acceleration. For this reason, we believe qualitative estimates of image quality and quantitative descriptions of contrast kinetics to be more relevant to clinical practice.…”

Section: Discussionmentioning

confidence: 98%

Improved Quality and Diagnostic Confidence Achieved by Use of Dose-Reduced Gadolinium Blood-Pool Agents for Time-Resolved Intracranial MR Angiography

Dehkharghani

Kang

Saindane

2013

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:Time-resolved MRA with the use of bolus injection of paramagnetic agents has proved valuable in neurovascular imaging. Standard contrast agents have limited blood-pool residence times, motivating the development of highly protein-bound blood-pool agents with greater relaxivity and longer intravascular residence, affording improved image quality at lesser doses. This study represents the first comparison of blood-pool agents to standard agents in time-resolved cerebral MRA.

show abstract

“…Multiple studies have demonstrated its safety. In phase III trials of Ablavar performing MR angiography of the aortoiliac region in adults patients with known or suspected to have peripheral vascular disease, the most common adverse events were feeling hot (4.4%), nausea (3.6%), headache (3.3%) and burning sensation (2.9%); the incidence of severe and serious adverse events was low (19,20). Of note, QTc prolongation has been reported following gadofosveset administration, and therefore patients should be assessed for a history of underlying conditions that may predispose to arrhythmias from QTc prolongation.…”

Section: Contrast Agentsmentioning

confidence: 99%

Blood pool contrast agents for venous magnetic resonance imaging

Oliveira¹,

Hedgire²,

Li³

et al. 2016

Cardiovasc. Diagn. Ther.

View full text Add to dashboard Cite

Imaging of the venous system plays a vital role in the diagnosis and management of a wide range of clinically significant disorders. There have been great advances in venous imaging techniques, culminating in the use of magnetic resonance venography (MRV). Although MRV has distinct advantages in anatomic and quantitative cross sectional imaging without ionizing radiation, there are well-known challenges in acquisition timing and contrast administration in patients with renal impairment. The latest advancement involves the addition of new contrast media agents, which have emerged as valuable alternatives in these difficult scenarios. In this review, we will focus on a group of specific contrast agents called blood pool agents and discuss their salient features and clinical applications.

show abstract

Aortoiliac Occlusive Disease in Patients with Known or Suspected Peripheral Vascular Disease: Safety and Efficacy of Gadofosveset-enhanced MR Angiography—Multicenter Comparative Phase III Study

Abstract: On the basis of substantial improvements over non-contrast MR angiography in efficacy and a minimal and transient side-effect profile, gadofosveset was found to be safe and effective for MR angiography in patients known or suspected to have peripheral vascular disease.

Cited by 86 publications

References 24 publications

Comparison of contrast‐enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of peripheral arterial occlusive disease: Results of a phase III multicenter trial

Comparison of contrast‐enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of peripheral arterial occlusive disease: Results of a phase III multicenter trial

Improved Quality and Diagnostic Confidence Achieved by Use of Dose-Reduced Gadolinium Blood-Pool Agents for Time-Resolved Intracranial MR Angiography

Blood pool contrast agents for venous magnetic resonance imaging

Contact Info

Product

Resources

About